- First Product Developed from the VisEn-Merck & Co., Inc. Biomarker Imaging Program -
- Expands VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio and Broadens Applications in Key Areas of Disease Research and Drug Development -
BEDFORD, Mass., Aug. 19 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its IntegriSenseTM fluorescence in vivo imaging agent product line. The agent is the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration announced in 2007, and will enable researchers to image and assess the role of integrin alpha v beta 3 in disease progression and therapeutic response in vivo.
IntegriSense is an optimized in vivo fluorescence imaging agent targeting integrin alpha v beta 3, a key biomarker closely associated with disease-related vascularity and angiogenesis. The agent was developed to enable in vivo imaging of integrin alpha v beta 3 expression in order to measure and monitor aspects of disease progression and therapeutic response in disease states including oncology, cardiovascular disease, and bone disease.
"The integrin alpha v beta 3 protein plays an important key role in many disease pathways, which is one of the key reasons we selected this as a first imaging target with our collaborators at Merck," said Kirtland Poss, President and CEO of VisEn Medical. "IntegriSense should enable researchers to drive valuable new insights into disease progression and therapeutic mechanisms of action in vivo. We are pleased to be providing our customers the continually expanding ability to generate such rich information on their disease biologies and pathways of interest."
VisEn's in vivo fluorescence imaging technologies, including its
Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic
Imaging Systems (FMT), provide the industry's most robust fluores
|SOURCE VisEn Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved